Last updated on April 2019

Study of Intratumoral CV8102 in cMEL cSCC hnSCC and ACC


Brief description of study

This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.

Patients will receive CV8102 as single agent or in combination with SoC anti-PD-1 therapy.

Clinical Study Identifier: NCT03291002

Contact Investigators or Research Sites near you

Start Over

Investigative Site

Erlangen, Germany
9.46miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.